Search - tctmd.com

Displaying 121 - 140 of 1583

Sort: Relevancy | Date

Weight-Loss Showdown: Is It Time for an RCT of Bariatric Surgery vs GLP-1s?

News Features

Weight-Loss Showdown: Is It Time for an RCT of Bariatric Surgery vs GLP-1s?

Michael O'Riordan

January 17, 2025

Change in Kidney Function With Finerenone Doesn’t Impact Treatment’s Benefit

News Daily News

Change in Kidney Function With Finerenone Doesn’t Impact Treatment’s Benefit

Michael O'Riordan

January 13, 2025

Variety of GLP-1 Drugs Help People Without Diabetes Lose Weight: Review

News Daily News

Variety of GLP-1 Drugs Help People Without Diabetes Lose Weight: Review

January 09, 2025

Coronary Sinus Reducer Overlooked in Review of Stable Angina Treatments

News Daily News

Coronary Sinus Reducer Overlooked in Review of Stable Angina Treatments

Michael O'Riordan

January 03, 2025

Top General Cardiology and Prevention News of 2024

News Daily News

Top General Cardiology and Prevention News of 2024

December 30, 2024

Tirzepatide Gets FDA Approval for Sleep Apnea in Adults With Obesity

News Daily News

Tirzepatide Gets FDA Approval for Sleep Apnea in Adults With Obesity

December 23, 2024

December 2024 Dispatch for the CV Team

News Opinion CV Team Dispatch

December 2024 Dispatch for the CV Team

December 20, 2024

Questions Raised Anew About Aspirin for Secondary Prevention of ASCVD

News Daily News

Questions Raised Anew About Aspirin for Secondary Prevention of ASCVD

December 06, 2024

CVD Risks Vary by Type of Menopausal Hormone Replacement Therapy

News Daily News

CVD Risks Vary by Type of Menopausal Hormone Replacement Therapy

December 04, 2024

Tirzepatide Bests Semaglutide for Weight Loss: SURMOUNT-5 Topline Results

News Daily News

Tirzepatide Bests Semaglutide for Weight Loss: SURMOUNT-5 Top-line Results

Michael O'Riordan

December 04, 2024

CMS Proposal Would Expand Medicare, Medicaid Coverage for GLP-1 Drugs

News Daily News

CMS Proposal Would Expand Medicare, Medicaid Coverage for GLP-1 Drugs

November 27, 2024

ZENITH: Novel Biologic Reduces Morbidity and Mortality in PAH

News Daily News

ZENITH: Novel Biologic Reduces Morbidity and Mortality in PAH

November 26, 2024

November 2024 Dispatch for the CV Team

News Opinion CV Team Dispatch

November 2024 Dispatch for the CV Team

November 26, 2024

Indian Patients Do Well on Dual-Combination Pills for Hypertension: TOPSPIN

News Conference News AHA 2024

Indian Patients Do Well on Dual-Combination Pills for Hypertension: TOPSPIN

November 22, 2024

ZODIAC: Decision-Support Tool Doesn’t Sway Lipid-Lowering Treatments in ACS

News Conference News AHA 2024

ZODIAC: Decision-Support Tool Doesn’t Sway Lipid-Lowering Treatments in ACS

Michael O'Riordan

November 21, 2024

Clues to Evolocumab Response Exist in Patients’ Genes: YELLOW III

News Conference News AHA 2024

Clues to Evolocumab Response Exist in Patients’ Genes: YELLOW III

November 21, 2024

Phase 2 Trial of Zerlasiran: Multiple doses of an siRNA Targeting Lipoprotein(a) over 60 weeks

Presentation AHA 2024

Phase 2 Trial of Zerlasiran: Multiple doses of an siRNA Targeting Lipoprotein(a) over 60 weeks

Presenter: Steven E. Nissen

November 18, 2024

Effects of Sacubitril-Valsartan on Prevention of Cardiotoxicity in High-Risk Patients Undergoing Anthracycline Chemotherapy: The SARAH Trial

Presentation AHA 2024

Effects of Sacubitril-Valsartan on Prevention of Cardiotoxicity in High-Risk Patients Undergoing Anthracycline Chemotherapy: The SARAH Trial

Presenter: Marcely Gimenes Bonatto

November 18, 2024

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

News Conference News AHA 2024

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

Michael O'Riordan

November 18, 2024

ARNI Lessens Anthracycline Cardiotoxicity in High-Risk Patients: SARAH

News Conference News AHA 2024

ARNI Lessens Anthracycline Cardiotoxicity in High-Risk Patients: SARAH

November 18, 2024

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.